Trial site
Nanchang People's Hospital
Nanchang, Jiangxi 330009, ChinaNot linked to an institution yet
- 16running trials
- 1closed trial
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 24 trials
- Phase 2/31 trial
- Status
- Recruiting9 trials
- Not yet recruiting5 trials
- Active, not recruiting2 trials
- Completed1 trial
- Lead sponsor
- Boehringer Ingelheim3 trials
- Pfizer2 trials
- Shanghai Junshi Bioscience Co., Ltd.2 trials
- BioNTech SE1 trial
- Celcuity Inc1 trial
- and 8 more
Running trials
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
NCT07876557· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Wenyan Chen, Bachelor
Not yet recruiting
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
NCT07745257· Phase 2· Sun Yat-sen University· Source
Contact: Wenyan Chen
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· Phase 3· BioNTech SE· Source
Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Wenyan Chen, Doctor
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· Phase 3· Celcuity Inc· Source
Contact: Nadene Zack, MS
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source
Contact: Yili Wang
Recruiting
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06568471· Phase 3· Hasten Biopharmaceutical Co., Ltd.· Source
Contact: Zhaohui Pei
Recruiting
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
NCT06682195· Phase 2· First Affiliated Hospital of Zhejiang University· Source
Contact: Yili Wang
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945· Phase 3· Daiichi Sankyo· Source
Contact: Study Coordinator
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Chunwei Xie
Active, not recruiting
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· Phase 3· Pfizer· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299· Phase 3· Gilead Sciences· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error